Veloxis Pharmaceuticals
Speciality pharmaceutical company focused on the development and commercialization of Envarsus.
Launch date
Employees
Market cap
-
Enterprise valuation
€1.2b (Public information from Nov 2019)
Cary North Carolina (HQ), Hørsholm Capital Region of Denmark (founding location)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 4.4m | 5.7m | - | - | - | - |
| % growth | - | 30 % | - | - | - | - |
| EBITDA | (1.2m) | (<1m) | 17.5m | 33.0m | - | - |
| % EBITDA margin | (27 %) | (13 %) | - | - | - | - |
| Profit | (1.3m) | (<1m) | 9.5m | 22.4m | - | - |
| % profit margin | (30 %) | (13 %) | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
$60.0m | Post IPO Debt | ||
$1.3b Valuation: $1.3b 227.3x EV/LTM Revenues -1772.7x EV/LTM EBITDA | Acquisition | ||
| Total Funding | - | ||
